Literature DB >> 6199543

alpha 2-macroglobulin production by cultured human melanoma cells.

A C Morgan.   

Abstract

alpha 2-Macroglobulin (alpha 2M) was identified in chemically defined spent medium of cultured human melanoma cells. This wide-spectrum protease inhibitor was subsequently shown to be synthesized and was secreted by 10 of 13 cultured melanoma cells but not by neoplastic cells of other histologic origins (0/5 breast, 0/2 colon, 0/2 lung, 0/2 glioblastomas, 0/1 neuroblastoma, 0/4 lymphoid). alpha 2M was also produced by one strain of fetal lung fibroblasts, as was previously shown, but not by two strains of normal fetal uveal melanocytes or two strains of fetal skin fibroblasts. Biochemical characterization of melanoma alpha 2M indicated that it has a similar tetrameric structure but is smaller in size than authentic serum alpha 2M. Preliminary studies indicated that melanoma alpha 2M can bind to protease and has possible functional capability.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199543

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  4 in total

1.  Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.

Authors:  J Bizik; A Lizonová; R W Stephens; M Grófová; A Vaheri
Journal:  Cell Regul       Date:  1990-11

2.  Tissue distribution of rat macroglobulins in tumour-bearing rats.

Authors:  N V Maltseva; R M Zorina; N V Mingaljev; N A Krajushkina; T S Chirikova; N A Zorin
Journal:  Int J Exp Pathol       Date:  1999-04       Impact factor: 1.925

3.  Localization of alpha 2-macroglobulin in human primary sarcomas and synthesis in established cell lines.

Authors:  M Grófová; E Larsson; A Bengtsson; J Bizik; B Westermark; J Pontén
Journal:  In Vitro Cell Dev Biol       Date:  1988-05

4.  A novel "salting-out" procedure for the isolation of tumor-derived exosomes.

Authors:  Zachary Brownlee; Kristi D Lynn; Philip E Thorpe; Alan J Schroit
Journal:  J Immunol Methods       Date:  2014-04-13       Impact factor: 2.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.